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Abstract: Chronic stable angina is an exceedingly prevalent condition with tremendous clinical, 
social, and financial implications. Traditional medical therapy for angina consists of beta-  blockers, 
calcium channel blockers, and nitrates. These agents decrease myocardial   oxygen demand and 
ischemia by reducing heart rate, lowering blood pressure, and/or   optimizing   ventricular loading 
characteristics. Unique in its mechanism of action, ranolazine is the first new antianginal agent 
approved for use in the US for chronic angina in over 25 years. By inhibiting the late inward 
sodium current (INa), ranolazine prevents pathologic intracellular calcium accumulation that leads 
to ischemia, myocardial dysfunction, and electrical instability. Ranolazine has been proven in 
multiple clinical trials to reduce the symptoms of angina safely and effectively and to improve 
exercise tolerance in patients with symptomatic coronary heart disease. These   benefits occur 
without reduction in heart rate and blood pressure or increased mortality. Although ranolazine 
prolongs the QTc, experimental data indicate that ranolazine may actually be antiarrhythmic. 
In a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraven-
tricular tachycardia, ventricular tachycardia, new-onset atrial fibrillation, and bradycardic 
events. Additional benefits of ranolazine under investigation include reductions in glycosylated 
hemoglobin levels and improved left ventricular function. Ranolazine is a proven antianginal 
medication in patients with symptomatic coronary heart disease, and should be considered as 
an initial antianginal agent for those with hypotension or bradycardia.
Keywords: chronic angina, myocardial ischemia, ranolazine, pharmacotherapy, antianginal, 
sodium current
Introduction
Although angina pectoris has been diagnosed and treated by physicians for over a 
century, initial therapies were of limited utility. Brandy, ether, chloroform, and ammo-
nia were commonly prescribed to such patients in the nineteenth century before the 
application of nitrates was first published in 1867.1 Today, cardiovascular disease has 
tremendous medical, social, and financial impacts on American lives. Approximately 
2400 Americans die from cardiovascular disease each day, with over nine million adults 
reporting angina pectoris.2 The estimated direct and indirect cost of coronary heart 
  disease alone in the US exceeds 150 billion dollars annually. For those fortunate to 
survive a coronary event, much of this burden derives from hospitalizations, physician 
visits, and lost productivity. Improving control of angina pectoris is critical to optimizing 
the patient’s clinical outcome, quality of life, and the social impact of this condition.
Chronic stable angina results from an imbalance between myocardial   oxygen supply 
and demand in the setting of a fixed atherosclerotic coronary plaque.   Modern treatment Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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for chronic angina consists of medications and revascu-
larization, with the latter serving primarily an adjunctive 
role.3,4 Conventional medical therapy improves the ischemic 
imbalance leading to angina by reducing the heart rate, 
blood pressure, and/or preload while optimizing ventricular 
contractility, leading to a reduction in myocardial oxygen 
demand (Table 1).
Therapeutic advances in treating patients with stable 
angina during the past half century were initially robust. 
  Beta-blockers, first introduced in 1962, have largely become 
the first-line treatment for patients with coronary heart disease 
because of the post-myocardial infarction mortality reduc-
tion seen with this class of agents.5–7 Revascularization for 
coronary heart disease began with coronary artery bypass 
graft surgery in 1967, followed by percutaneous transluminal 
coronary angioplasty in 1977. However, after the introduc-
tion of calcium channel blockers in the 1980s, it was not until 
ranolazine was approved by the Food and Drug Aministra-
tion in 2006 that a novel medical therapy became available 
for the treatment of chronic stable angina. Ranolazine is a 
proven antianginal agent that, unlike beta-blockers, nitrates, 
or calcium channel blockers, does not affect either heart 
rate or blood pressure.8 Understanding ranolazine’s unique 
mechanism of action has led to the discovery of several 
investigational applications beyond the control of chronic 
angina symptoms.
Mechanism of action
Under normal physiologic conditions, cardiac myocyte func-
tion is characterized by a balance between sodium influx and 
efflux mechanisms. Cellular depolarization results from rapid 
activation of membrane sodium channels (peak INa) lead-
ing to inward flux of sodium ions (Phase 0).9 The peak INa 
channels rapidly inactivate, leading to a sustained but short 
intracellular accumulation of sodium (Phase 2). The intracel-
lular sodium then permits release of calcium intracellularly 
from the sarcoplasmic reticulum, which binds with actin 
and myosin, leading to myocardial contraction. Intracellular 
homeostasis is restored, with transport of the sodium and 
  calcium extracellularly by the sodium/potassium-ATPase 
(Na+/K+-ATPase) and the sodium/calcium (Na+/Ca2+) 
exchanger, respectively.
In pathologic states, such as ischemia, left ventricular 
hypertrophy, and heart failure, there is a prolonged late 
sodium current (late INa) during Phase 2 of the action 
potential.9,10 Excess intracellular sodium results in intra-
cellular Ca2+ overload via reverse transport across the 
Na+/Ca2+ exchanger. Sustained myocardial contraction 
ensues,   eventually leading to myocardial dysfunction, 
electrical instability, increased diastolic wall tension, and 
mitochondrial dysfunction.11 Ultimately, the increased 
diastolic wall tension causes compression of the vascular 
beds, leading to further reduction of coronary blood flow, 
increased myocardial oxygen demand, and eventual cellular 
necrosis (Figures 1 and 2).
Original investigations of ranolazine attributed its anti-
ischemic effects primarily to selective inhibition of fatty 
acid oxidation, thus shifting metabolism to more energy-
efficient glucose oxidation.12–15 Alternative explanations 
of ranolazine’s mechanism of action involving β1- and 
β2-adrenoceptor inhibition have also been proposed.16 
Subsequent studies, however, have largely disproven these 
theories and concluded that ranolazine’s mechanism of 
action, at therapeutic serum levels, primarily involves inhi-
bition of the late INa.17–19 By inhibiting the late INa, ranolazine 
prevents intracellular calcium overload and its subsequent 
deleterious electrical and mechanical effects. Therefore, 
under ischemic conditions, ranolazine’s effects are two-fold. 
First, it attenuates the abnormally prolonged and dysfunc-
tional myocardial contraction that increases myocardial 
oxygen demand. At the same time, ranolazine is thought to 
improve coronary blood flow and myocardial oxygen sup-
ply by optimizing diastolic function. Ranolazine appears 
to have little effect on normal resting myocytes, where the 
contribution of late INa is minimal.20 Thus, ranolazine targets 
a unique downstream component of the ischemic cascade, 
only under pathologic conditions, to provide its antianginal 
benefit (Figure 3).
While inhibition of the late INa by ranolazine causes 
shortening of the action potential duration, it also inhibits 
the delayed potassium rectifier (IKr), which can lengthen 
Table 1 Antianginal pharmacologic management
Determinant of  
O2 Demand
β- 
Blocker
Nitrates Ca++ Blocker Ca++  
Blocker
Dihydropyridine  Verap/ 
Dilt
Heart rate ↓↓ 0 ↑/↑↑ ↓↓
Afterload (BP) ↓ ↓ ↓↓↓↓ ↓↓
Preload 0 ↓↓↓ 0 0
Contractility ↓↓ ↑ ↑↑ ↓↓
Determinant of  
O2 supply
Vasomotor tone ↑ ↓↓ ↓↓↓↓ ↓↓↓↓
Abbreviations: BP, blood pressure; verap/dilt, verapamil/diltiazem; 0, no effect. 
Reprinted from Stone P. Ranolazine: new paradigm for management of myocardial 
ischemia, myocardial dysfunction, and arrhythmias. Cardiol Clin. 2008;26:603–614.58 
Copyright © 2008, with permission from elsevier. Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
519
Ranolazine in management of angina
the action potential duration.21 Lengthening of the action 
potential duration, early afterdepolarizations, delayed 
afterdepolarizations, triggered activity, and increased trans-
mural dispersion are each a substrate for ventricular and 
atrial arrhythmias. The net effect of ranolazine, however, 
depends on the relative concentrations of these channels in 
the myocardium and conduction system. Late INa channels 
are abundant within the Purkinje fibers and midmyocardial 
cells, resulting in a shortening of the action potential dura-
tion. Moreover, several preclinical trials have demonstrated 
that ranolazine actually reduces afterdepolarizations, delayed 
afterdepolarizations, triggered activity, and transmural 
dispersion, suggesting a potential antiarrhythmic effect of 
ranolazine.21–25
Clinical applications
Stable angina
Several clinical trials have investigated the use of ranolazine 
in patients with chronic stable angina. Although ranolazine is 
available as both an oral and intravenous formulation, only the 
oral sustained-release (SR) formulation is available for clini-
cal use, and was the primary agent used in the clinical trials. 
However, the initial study investigating the use of   ranolazine in 
chronic stable angina compared   immediate-release   ranolazine 
with atenolol and placebo in a randomized, double-blind, 
crossover design involving 158 patients.26 Compared with 
placebo, ranolazine significantly improved time to angina 
onset, time to ST segment depression, and total exercise 
duration, while only the latter was significantly improved 
when compared with atenolol. All subsequent   clinical trials 
used the SR formulation of ranolazine.
MARiSA trial
In the Monotherapy Assessment of Ranolazine in Stable 
Angina (MARISA) trial, 191 patients with angina-limited 
exercise were randomized to ranolazine SR 500 mg, 1000 mg, 
1500 mg, or placebo twice daily for one week in a double-
blind, four-period, crossover, multicenter study.12 All other 
antianginal therapy, except for sublingual nitroglycerin, was 
discontinued prior to enrollment. Patients were excluded 
if the following conditions were present: non-diagnostic 
electrocardiogram, New York Heart Association Class III 
or IV congestive heart failure, unstable angina, myocardial 
infarction, recent (,two months) coronary revascularization, 
corrected QT (QTc) interval .500 msec, or any medication 
known to prolong the QT interval or affect metabolism of 
cytochrome P450 (CYP) 3A4. Eligible patients were required 
to have exercise-limiting angina with $1 mm horizontal or 
downsloping ST depression on exercise treadmill testing 
during a qualifying enrollment phase.
Exercise testing was performed at the conclusion of each 
treatment phase, during both peak (four hours after dosing) 
and trough (12 hours after dosing) plasma ranolazine concen-
trations, to assess the sustainability of a clinical response and 
establish a dose-response relationship. The MARISA investi-
gators found that ranolazine 500 mg, 1000 mg, and 1500 mg 
twice daily incrementally increased exercise duration by 94 
sec, 103 sec, and 116 sec, respectively. These improvements 
were all significant (P , 0.005) when compared with placebo. 
Furthermore, dose-related increases in exercise duration at 
peak, as well as trough, and peak times to 1 mm ST segment 
depression, and times to angina onset were also demonstrated 
(P , 0.005) (Figure 4).
Safety analysis from MARISA yielded several interest-
ing conclusions. Although ranolazine did prolong the QTc 
by 6–14 msec in a dose-dependent fashion, no patient was 
discontinued from the study because of QT prolongation. 
Overall, adverse events were substantially more common with 
the 1500 mg twice-daily dose compared with the lower doses 
of ranolazine, leading to higher rates of early withdrawal from 
the study at this dose. Finally, unlike traditional agents used 
to treat chronic angina, there were no clinically significant 
changes in either heart rate or blood pressure at rest or dur-
ing exercise. In this first major clinical trial in patients with 
chronic stable angina, ranolazine SR monotherapy improved 
exercise performance in a dose-dependent fashion, with an 
acceptable safety profile and without clinically meaningful 
hemodynamic alterations.
CARiSA trial
The Combination Assessment of Ranolazine in Stable Angina 
(CARISA) trial investigated 823 adults with chronic angina 
on concurrent therapy with beta-blockers or calcium channel 
blockers.27 In a randomized, three-group, parallel, double-
blind, placebo-controlled design, patients were randomly 
assigned to placebo, or ranolazine 750 mg or 1000 mg. 
Qualifying antianginal therapy at the time of enrollment was 
atenolol 50 mg, a once-daily diltiazem 180 mg formulation, 
or amlodipine 5 mg once a day, which was continued through-
out the study. Patient selection was otherwise similar to that 
described in the MARISA trial. Treadmill exercise responses 
were assessed after two, six, and 12 weeks of treatment, at 
both peak and trough drug intervals.
The primary endpoint, exercise duration, was signifi-
cantly improved in both ranolazine groups (pooled) versus 
the placebo group (115.6 sec versus 91.7 sec, respectively, Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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P = 0.01). Exercise duration was increased with ranolazine 
at both trough and peak, with greater benefit seen at peak 
concentrations. The response was sustained throughout the 12 
weeks of therapy and independent of background   antianginal 
therapy (Figures 5 and 6).
Ranolazine significantly reduced the mean number of 
angina attacks per week from 3.3 with placebo to 2.5 and 
2.1 with ranolazine 750 mg and 1000 mg, respectively. 
Consistent with these findings, nitroglycerin consumption 
was also significantly reduced with ranolazine compared 
with placebo, in a similar dose-dependent fashion. Improve-
ments in exercise performance, number of angina attacks, 
and nitroglycerin consumption were all seen in the absence 
of alterations in heart rate or blood pressure. The QTc 
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Figure 1 ionic disturbances in ischaemia and heart failure, and their consequences. Belardinelli L, Antzelevitch C, Fraser H. inhibition of late (sustained/persistent) sodium 
current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004;6 
(Suppl i):13–17.11 By permission Oxford University Press, copyright © 2004.
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Figure 2 Relation between peak and late sodium current and ventricular action potential (AP) and contraction (tracings are not actual recordings). Panels A and B illustrate 
a normal and an increased late iNa (due to impaired inactivation of Na+ channel), respectively. The enhanced late iNa is accompanied by delayed ventricular repolarization 
(longs APs, and occasional early after depolarization) and abnormal twitch (contraction composed of a phasic and tonic component.) Belardinelli L, Antzelevitch C, Fraser 
H. inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on 
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was prolonged 6.1 msec and 9.2 msec by the 750 mg and 
1000 mg doses, respectively. No episodes of torsades de 
pointes were observed.
While the MARISA trial demonstrated ranolazine’s effi-
cacy as monotherapy for patients with chronic angina, the 
CARISA trial was able to demonstrate similar antianginal 
benefit in those who remained symptomatic despite standard 
doses of traditional antianginal therapies.
eRiCA trial
The objective of the Efficacy of Ranolazine in Chronic 
Angina (ERICA) trial was to determine if ranolazine   provided 
additional benefit superimposed on maximal dosing of a 
conventional antianginal agent. In ERICA, 565 patients 
with symptomatic ($three angina attacks per week) chronic 
angina despite amlodipine 10 mg daily were randomized to 
placebo versus ranolazine 1000 mg twice daily.28 Treatment 
was double-blinded and continued for six weeks. Patient 
selection was otherwise similar to the previous clinical trials. 
However, unlike the antecedent trials, the primary endpoint 
was the frequency of anginal episodes per week, and exercise 
testing was not performed.
Baseline characteristics were similar between groups, 
with an average angina frequency of 5.63 ± 0.18 episodes per 
week and nitroglycerin consumption of 4.72 ± 0.21 tablets 
per week. Compared with placebo, ranolazine significantly 
reduced the frequency of angina attacks (2.88 ± 0.19 on 
ranolazine versus 3.31 ± 0.22 on placebo; P = 0.028) and 
nitroglycerin consumption (2.03 ± 0.20 on ranolazine versus 
2.68 ± 0.22 on placebo; P = 0.014). Although these results were 
evident across all subgroups, those with .4.5 anginal episodes 
per week derived a greater treatment effect (Figure 7).
Consistent with the previous clinical trials, ranolazine 
was well tolerated without significant adverse events. Vital 
signs remained constant over the treatment period, again 
highlighting a unique nonhemodynamic effect profile among 
the currently available antianginal agents. By demonstrat-
ing that ranolazine could relieve symptoms in patients with 
chronic angina on maximal doses of amlodipine, ranolazine 
was approved in 2006 by the Food and Drug Administration 
for use in chronic stable angina.29
In a recent pilot study, ranolazine up to 1000 mg 
twice daily was administered to 20 patients with coronary 
heart disease and who had reversible perfusion defects 
on exercise treadmill gated single-photon emission com-
puted tomography myocardial perfusion imaging while 
on conventional antianginal therapy.30 Repeat treadmill 
myocardial perfusion imaging was performed four weeks 
later, in which quantitative analysis showed significant 
reductions in the summed stress scores (P = 0.04), summed 
difference scores (P = 0.0037), and reversible abnormality 
on the polar maps (P , 0.05). Taken together, these myo-
cardial perfusion imaging findings support an objective 
improvement in myocardial blood flow with ranolazine. 
Although this study was limited by lack of randomiza-
tion, blinding, or a large study   population, ranolazine was 
shown to improve myocardial perfusion and decrease the 
ischemic burden.
Development of Ischemia Consequences of Ischemia
O2 Demand
O2 Supply
Ischemia
(Ca++overload)
Ranolazine
Compression
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blood vessels
• Heart rate
• Blood pressure
• Preload
• Contractility
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• Myocardial dysfunction
(↓ systolic function/
 ↑ diastolic stiffness)
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anti-ischemic
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Figure 3 Sites of action of anti-ischemia medication. Reprinted from Stone P. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and 
arrhythmias. Cardiol Clin. 2008;26:603–614.58 Copyright © 2008, with permission from elsevier.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Acute coronary syndrome
MeRLiN study
Although ranolazine had been proven to be safe and 
efficacious in treating angina for those with chronic stable 
disease, higher-risk populations had yet to be examined. 
In the Metabolic Efficiency With Ranolazine for Less 
Ischemia in Non-ST-Elevation Acute Coronary Syndromes 
(MERLIN)-TIMI 36 trial, 6560 patients were randomized in 
a double-blind, placebo-controlled, multinational design to 
ranolazine or placebo within 48 hours of their non-ST eleva-
tion acute coronary syndrome presentation.31 Ranolazine was 
initially administered intravenously, followed by oral dosing 
at 1000 mg twice daily. Continuous Holter monitoring was 
performed for seven days after the index event, and median 
follow-up was 348 days.
Analysis of the primary endpoint (a composite of 
cardiovascular death, myocardial infarction, or recurrent 
ischemia) showed no significant difference between the 
ranolazine and placebo groups (696 patients [21.8%]   versus 
753 patients [23.5%] respectively; P = 0.11). When the 
individual elements were evaluated, neither cardiovascular 
death nor myocardial infarction was found to be significantly 
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different. The incidence of recurrent ischemia, however, was 
significantly lower in the ranolazine group compared with 
the placebo group (430 patients [13.9%] versus 494 patients 
[16.1%], respectively; P = 0.03). This benefit is likely to be 
a long-term effect, because post-analysis of the seven-day 
Holter monitoring post-index event showed no significant 
difference in the rate of ischemia detected by electrocardio-
gram (Figure 8).32
Although no significant difference was found in the pri-
mary endpoint across most major subgroups in the MERLIN 
trial, including patients treated with intent for a noninvasive 
strategy, one interesting post hoc analysis result was found 
with respect to women. Subgroup analysis of the clinical trials 
using ranolazine prior to MERLIN had found that women 
showed less improvement than men on exercise testing, with 
similar improvements in angina frequency and nitroglycerin 
consumption.33 In the MERLIN trial, however, the effect of 
ranolazine on the primary endpoint was significant among 
women (n = 2291; hazard ratio 0.83; 95% confidence interval 
0.70–0.99), largely driven by a 29% relative reduction in 
recurrent ischemia with ranolazine (P = 0.002). Further stud-
ies are needed to help reconcile these discrepancies.
Unlike previous trials, which used ranolazine only in 
stable coronary heart disease patients, the MERLIN trial 
studied a higher-risk population of patients with non-ST ele-
vation acute coronary syndrome. Safety analysis showed no 
significant difference in death from any cause with ranolazine 
compared with placebo (172 versus 175; P = 0.91). The inci-
dence of symptomatic documented arrhythmias throughout 
the duration of the study was also similar in patients treated 
with ranolazine compared with placebo (P = 0.84). Interest-
ingly, the frequency of clinically significant arrhythmias 
detected by Holter monitoring within the first seven days was 
significantly lower in the ranolazine group compared with the 
placebo group (2330 patients [73.7%] versus 2650 patients 
[83.1%]; P , 0.001), a result to be discussed in more detail 
further on in the article.
A recently published subgroup analysis of 3565 patients 
with prior chronic angina enrolled in the MERLIN trial dem-
onstrated that, in addition to reducing recurrent ischemia, 
ranolazine was effective in reducing worsening angina and 
intensification of antianginal therapy while improving exer-
cise duration.34 Conclusions from the MERLIN trial further 
support previous clinical trial data that ranolazine is effective 
in controlling angina in symptomatic patients with chronic 
coronary heart disease. Moreover, ranolazine has a favorable 
safety profile, even in higher-risk acute coronary syndrome 
groups, but does not afford any significant reduction in major 
cardiovascular events, including all-cause death. Beyond its 
proven antianginal effect, ranolazine may be an effective antiar-
rhythmic agent, warranting further investigation (Table 2).
Safety
Individually, clinical trial data demonstrate that ranolazine is 
generally well tolerated without significant adverse events. 
The most common adverse events reported include dizzi-
ness, constipation, nausea, asthenia, syncope, headache, and 
abdominal pain. In the MARISA trial, adverse events were 
markedly lower, ie, # 20.6% versus 33.2% with ranolazine 
dosages at 1000 mg twice daily or less, compared with 
1500 mg twice daily.12 Subsequently, ranolazine 1000 mg 
twice daily became the maximum recommended dose. 
Although five cases of syncope were reported in the CARISA 
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trial, which used a maximum 1000 mg twice-daily dose, all 
cases involved patients on concurrent medications known to 
raise ranolazine plasma concentrations.27 Furthermore, there 
were no reported cases of syncope in the ERICA trial.28
The Ranolazine Open Label Experience (ROLE) trial 
enrolled 746 patients who completed either the MARISA 
or CARISA trials, with severe functional impairment from 
angina (mean Duke Treadmill score -14.4), in an open-label 
extension program.35 After a mean follow-up of 2.82 years, 
72 patients (9.7%) discontinued ranolazine due to adverse 
events. Of the reported adverse events, dizziness (11.8%) and 
constipation (10.9%) were the most common. Although the 
mean QTc was prolonged by 2.4 msec, there were no treat-
ment discontinuations because of QTc prolongation and no 
reported cases of torsades de pointes. When combining data 
from the original two trials with that from the ROLE program, 
the annual mortality for patients with stable coronary heart 
disease exposed to ranolazine was 2.8% compared with .5% 
as predicted by the Duke Treadmill score. Consistent with 
these findings, the MERLIN trial demonstrated that, even 
in higher-risk patients with non-ST segment acute coronary 
syndrome, there was no increased cardiovascular death or 
total mortality with ranolazine.31
In evaluating the safety of ranolazine, several specified 
populations were investigated with encouraging findings. 
Patients with congestive heart failure enrolled in the ROLE 
program had lower rates of withdrawal.35 As may be expected, 
the elderly population had higher rates of adverse events, 
leading to higher rates of ranolazine discontinuation.35,36 
Serious adverse events attributed to ranolazine, however, did 
not differ by age group. Similarly, the presence of diabetes, 
a common comorbidity in patients with coronary heart 
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Figure 8 Kaplan–Meier estimated Rates of Cardiovascular Death or Mi and Recurrent ischemia. Reprinted with permission from Morrow DA, Scirica BM, Karwatowska-
Prokopczuk e, et al. effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. JAMA. 2007;297:1775–1783.31 
Copyright © 2007 American Medical Association. All rights reserved.
Abbreviations: Mi, myocardial infarction; HR, hazard ratio; CI, confidence interval.
Table 2 Efficacy outcomes
Ranolazine 
(n = 1,789)
Placebo 
(n = 1,776)
Hazard ratio  
(95% Cl) 
p value
Randomization to end of study
  Primary end point* 443 (25.2) 503 (29.4) 0.86 (0.75–0.97) 0.017
  Major secondary end point† 379 (21.2) 414 (23.5) 0.89 (0.78–1.03) 0.12
  CV death or Ml 214 (11.9) 221 (12.5) 0.97 (0.80–1.16) 0.71
  Recurrent ischemia 277 (16.5) 344 (21.1) 0.78 (0.67–0.91) 0.002
  Worsening angina 96 (5.6) 124 (8.1) 0.77 (0.59–1.00) 0.048
  Severe recurrent ischemia 204 (11.9) 245 (14.4) 0.81 (0.67–0.98) 0.026
  Intensification of antianginal therapy 205 (12.5) 260 (16.4) 0.77 (0.64–0.92) 0.005
30 days until end of study (Landmark analysis)
  Primary end point 338 (19.8) 386 (23.3) 0.86 (0.74–0.99) 0.039
  Recurrent ischemia 226 (13.7) 274 (17.2) 0.80 (0.67–0.96) 0.015
  Worsening angina 92 (5.4) 120 (7.9) 0.76 (0.58–0.99) 0.044
Notes: Data are reported as n (%), event rates in parentheses are Kaplan–Meier estimates (%) at 1 year. *Cardiovascular (CV) death, myocardial infarction (Ml), or recurrent 
ischemia. †CV death. Ml, or severe recurrent ischemia.
Reprinted from Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina: observations from the randomized, double-blind, placebo-controlled 
MERLIN-TIMI (metabolic efficiency with ranolazine for less ischemia in non-ST-segment elevation acute coronary syndromes) 36 trial. J Am Coll Cardiol. 2009;53:1510–1516.34 Copyright 
© 2009, with permission from elsevier.
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disease, was not found to be a predictor of increased adverse 
events for patients on ranolazine.37 Ranolazine appears to be 
well tolerated, with an acceptable adverse event profile and 
without increased mortality in the general population with 
coronary heart disease, including the elderly and those with 
diabetes or congestive heart failure.
Pharmacokinetics and metabolism
Ranolazine is available in both oral and intravenous formula-
tions, with only the SR 500 mg tablets approved for clinical 
use. The oral bioavailability ranges from 35% to 50%, with 
food having no effect on the rate or extent of absorption.38 
The time to maximal plasma concentration with the SR 
formulation is 4–6 hours, with a peak-trough ratio at steady 
state ranging from 1.8–2.2. Effective plasma concentrations, 
based on clinical trials, range from 2–6 µmol/L.20
Ranolazine is extensively metabolized by CYP3A4 
enzymes and, to a lesser extent, by CYP2D6. Approximately 
5% is excreted renally unchanged, with advancing degrees of 
renal failure increasing plasma ranolazine concentrations by 1.7 
to 2.0.39 Although mild hepatic impairment has no detectable 
effect on ranolazine metabolism, moderate hepatic impairment 
significantly increases ranolazine plasma concentrations.40
Due to its principal CYP3A4-mediated metabolism, 
multiple drug-drug interactions are seen with ranolazine. 
  Moderate to potent inhibitors of the CYP3A4 enzyme 
(ketoconazole, diltiazem, verapamil, macrolide antibiotics, 
protease inhibitors, and grapefruit juice) can increase 
plasma ranolazine concentrations by 2.0- to 4.5-fold.41 
Therefore, caution is advised for inhibitors of CYP3A4 
when administered with ranolazine. Simvastatin and digoxin 
do not   significantly alter ranolazine levels. The plasma 
  concentrations of these drugs, however, are increased by 
2.0- and 1.5-fold, respectively, when given with ranolazine. 
Inhibitors of P-glycoprotein, verapamil, and cyclosporine 
can increase the absorption of ranolazine, and similar con-
siderations should be applied.
Investigational clinical applications
Arrhythmias
Despite the modest QTc prolongation seen with ranolazine 
in clinical trials, both experimental and clinical data support 
a potential antiarrhythmic role for this proven antianginal 
agent. Ranolazine has multiple cardiac ion channel effects. 
However, at therapeutic plasma levels, ranolazine primarily 
inhibits late INa and IKr.21 Inhibition of these two channels have 
opposing effects on the action potential duration, with the 
net effect of ranolazine dependent on the relative concentra-
tions of these channels within the midmyocardial cells and 
Purkinje fibers (Figure 9).
Prolongation of the action potential duration, in associa-
tion with early afterdepolarizations, delayed afterdepolariza-
tions, increased transmural dispersion of repolarization, and 
triggered activity are substrates for both atrial and ventricular 
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Figure 9 Summary of concentration-response relationships for effect of ranolazine to inhibit inward and outward ion channel currents in canine ventricular myocytes. Numbers 
inside parentheses are iC50 values for effect of ranolazine to inhibit rapidly activating delayed rectifier potassium current (IKr), late sodium current (late iNa), peak calcium current 
(iCa), late iCa, and sodium–calcium exchange current (iNa - iCa). Reprinted with permission from Antzelevitch C, Belardinelli L, Zygmunt AC, et al. electrophysiological effects of 
ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904–910.21 Copyright © 2004 Wolters Kluwer Health.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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arrhythmias, including ventricular tachycardia, torsades de 
pointes, and atrial fibrillation.23 Multiple experimental ani-
mal models involving coronary ischemia and/or exposure 
to proarrhythmic compounds have demonstrated significant 
reductions in action potential duration, early afterdepolariza-
tions, delayed afterdepolarizations, transmural dispersion of 
repolarization, and triggered activity with ranolazine.21–23,25
Based on these preclinical findings, several animal and 
limited human case studies have investigated ranolazine’s 
potential antiarrhythmic role. In a study using isolated canine 
right atrium, ranolazine equaled amiodarone in preventing 
acetylcholine-induced atrial fibrillation.42 A small human 
case series of seven patients with persistent atrial fibrilla-
tion despite ablation and/or conventional antiarrhythmic 
  medications found that four patients remained in sinus 
rhythm with ranolazine at a mean duration of 27 weeks.43 
Similarly, in a study of 18 patients with new or paroxysmal 
atrial   fibrillation, ranolazine was administered as a single 
2000 mg dose using a “pill in the pocket” strategy. Thirteen 
of 18 patients converted to sinus rhythm within six hours, 
suggesting that ranolazine might be useful for acute medical 
cardioversion of atrial fibrillation.44 In a recent published 
study of isolated right atrial appendages from patients 
with permanent (or chronic) atrial fibrillation, ranolazine 
  significantly decreased late INa, while reversing proarrhythmic 
activity induced by high Ca2+ or isoprenaline.45
Ranolazine has also been applied to various models of 
ventricular tachycardia and ventricular fibrillation with prom-
ising results. In a study of 29 anesthetized pigs, ranolazine 
administration significantly increased the ventricular fibrilla-
tion threshold during invasive electrophysiologic study while 
having no effect on the defibrillation threshold.46 These results 
were seen in the setting of an average QTc prolongation of 27 
msec. In an animal model of ischemia/reperfusion-induced 
ventricular arrhythmias, 23 rats underwent transient occlusion 
of their left coronary arteries with and without ranolazine. 
While 9/12 (75%) of placebo-treated rats developed ven-
tricular tachycardia, only 1/11 (9%) treated with ranolazine 
developed ventricular tachycardia.47   Sixty-seven percent of 
placebo-treated rats developed ventricular fibrillation com-
pared with 8% of rats treated with higher doses of ranolazine. 
In a similar study using a rat model of drug-induced torsades 
de pointes, ranolazine was shown to prevent the develop-
ment of torsades de pointes significantly and to terminate 
torsades de pointes after the first episode.48 Human studies 
with ranolazine and ventricular arrhythmias are   limited. In a 
high-risk group of patients with hereditary long QT syndrome 
(LQT3-∆KPG) prone to ventricular arrhythmias and sudden 
cardiac death, ranolazine shortened the QTc by 26 ± 3 msec 
(P , 0.0001) and improved diastolic relaxation parameters.49 
Although the preclinical antiarrhythmic data on ranolazine 
are promising, these studies are limited.
Certainly, the most robust data investigating the poten-
tial antiarrhythmic properties of ranolazine came from the 
MERLIN trial. Of 6560 patients hospitalized with a non-ST 
elevation acute coronary syndrome enrolled in the trial and 
randomized to placebo or ranolazine, 6351 (97%) had con-
tinuous Holter monitoring for the first seven days after the 
index events, and were suitable for evaluation.50 Treatment 
with ranolazine resulted in significantly fewer episodes of 
ventricular tachycardia lasting $ eight beats (P , 0.001) 
and supraventricular tachycardia (P , 0.001), but had no 
Table 3 Rate of tachyarrhythmias detected on ceCG monitoring after non-ST-segment elevation Mi
Ranolazine, 
n (%)
Placebo, 
n (%)
RR 
(95% Cl)
p
Ventricular arrhythmias
  VT $3 beats $100 bpm 1646 (52.1) 1933 (60.6) 0.86 (0.82, 0.90) ,0.001
  VT $4 beats $100 bpm 662 (20.9) 941 (29.5) 0.71 (0.6, 0.78) ,0.001
  VT $8 beats (lasting ,30s) 166 (5.3) 265 (8.3) 0.63 (0.52, 0.76) ,0.001
  Polymorphic VT $8 beats 38 (1.2) 46 (1.4) 0.83 (0.54,1.28) 0.40
  Sustained VT ($30s) 14 (0.44) 14 (0.44) 1.01 (0.48,2.13) 0.98
    Monomorphic 4 (0.13) 7 (0.22) 0.59 (0.17,2.06) 0.37
    Polymorphic 10 (0.32) 7 (0.22) 1.41 (0.52, 3.78) 0.46
Supraventricular arrhythmias
  New-onset atrial fibrillation 55 (1.7) 75 (2.4) 0.74 (0.52,1.05) 0.08
    Other SVT $120 bpm lasting 
at least 4 beats
1413 (44.7) 1752 (55.0) 0.81 (0.77, 0.85) ,0.001
Reproduced with permission from Scirica BM, Morrow DA, Hod H, et al. effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of 
arrhythmias in patients with non-ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary 
syndrome-thrombolysis in myocardial infarction 36 (MeRLiN-TiMi 36) randomized controlled trial. Circulation. 2007;116:1647–1652.50 Copyright © 2007 Wolters Kluwer Health.
Abbreviations: VT, ventricular tachycardia; SVT, supraventricular tachycardia.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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effect on sustained ventricular tachycardia greater than 30 
seconds. It is possible that the absolute number of sustained 
ventricular tachycardia episodes was too low to reach any 
significant conclusions (Table 3).
There was a trend toward lowering of the occurrence 
of new-onset atrial fibrillation (P = 0.08), while ranolazine 
significantly reduced the incidence of pauses $ three seconds 
compared with placebo (P = 0.01). Based on these findings, 
in conjunction with consistent preclinical data, ranolazine 
appears to be antiarrhythmic. The QTc prolongation seen 
with ranolazine does not confer an increased arrhythmic risk. 
Considering that the etiology for many of these arrhythmias 
is not ischemic in nature, it is plausible that ranolazine’s 
antiarrhythmic properties are related to direct ion channel 
effects. However, the anti-ischemic effects of ranolazine may 
contribute benefit for ischemia-related arrhythmias. Subse-
quent trials are needed to support these findings, including 
trials investigating the use of ranolazine in patients taking 
medications known to prolong the QTc.
Heart failure
As previously described, ischemia and heart failure lead to 
abnormally increased late INa current and intracellular cal-
cium overload.9,10 Ultimately, excess intracellular calcium 
leads to dysfunctional myocardial contraction, increased 
diastolic wall tension, decreased myocardial perfusion, and 
worsening myocardial function.11 By inhibiting the late INa 
current, investigations into whether ranolazine can improve 
both diastolic and systolic cardiac function have been 
performed.
One of the earliest trials involved 15 patients with previous 
transmural infarction who underwent invasive hemodynamic 
and angiographic assessment before and after administration 
of ranolazine.51 In the ischemic but not infarcted segments, 
ranolazine significantly increased the regional peak filling 
rate (P , 0.05) and regional wall lengthening during the 
isovolumic relaxation period (P , 0.05), which indicates 
an improvement in regional diastolic function. In a canine 
model of heart failure induced by sequential intracoronary 
microembolization, ranolazine reversibly shortened the 
duration of twitch contractures and completely abolished 
aftercontractures, effectively reducing diastolic wall “ten-
sion”.24 Further adding to the evidence that ranolazine can 
improve diastolic function, isolated perfused rat hearts were 
subjected to transient ischemia followed by reperfusion. 
Compared with placebo, ranolazine delayed the onset of 
ischemic contracture, reduced the average left ventricular 
end diastolic pressure during ischemia and reperfusion, and 
increased coronary flow at the end of reperfusion.27 Several 
other in vitro   studies with ranolazine using isolated rat 
hearts and isolated myocardium from failing human hearts 
have shown similarly significant reductions in diastolic wall 
tension and left ventricular end diastolic pressure, while 
improving coronary perfusion.45,52–54 These studies have 
inherent limitations, but provide compelling mechanistic and 
in vitro data to support further investigation and potential use 
of ranolazine to treat diastolic heart failure.
Beyond diastolic applications, ranolazine has been 
applied to several systolic heart failure models with intriguing 
results. Chronic heart failure was induced in 13 dogs using 
intracoronary microembolization followed by   hemodynamic 
and angiographic analysis before and after ranolazine 
  infusion.14 Ranolazine markedly increased the left ventricular 
ejection fraction (27% versus 36%; P = 0.0001) and stroke 
volume (20 mL versus 26 mL) without altering heart rate or 
systemic blood pressure.
To investigate ranolazine’s effect on left ventricular func-
tion and infarct size in the setting of acute ischemia, anesthe-
tized rabbits were pretreated with either ranolazine infusion or 
vehicle prior to coronary artery occlusion and reperfusion.55 
Rabbits treated with ranolazine had better global left ven-
tricular ejection fraction (0.42% versus 0.33%; P , 0.007), 
stroke volume (1.05 mL versus 0.78 mL; P , 0.01) and 
smaller infarct size (44% versus 57%; P , 0.04). These 
findings argue that ranolazine may improve left ventricular 
systolic function and provide myocardial protection during an 
acute myocardial infarction. Finally, two similar dog models 
of heart failure induced by intracoronary microembolization 
found that treatment with ranolazine not only improved left 
ventricular systolic function while reducing pathologic myo-
cardial remodeling, but these results occurred in the absence 
of any increase in myocardial oxygen consumption.56,57 In 
summary, by inhibiting the late INa and preventing pathologic 
intracellular calcium accumulation in heart failure and isch-
emic conditions, ranolazine may be useful in preventing the 
abnormal myocardial remodeling that leads to systolic and 
diastolic heart failure.58
Diabetes
The presence of diabetes in patients with coronary heart 
disease confers an increased risk of cardiovascular morbid-
ity and mortality.59 In the previous clinical trials of ranola-
zine in patients with stable coronary heart disease, focused 
analysis of the diabetic population has yielded interesting 
results. In the CARISA trial, ranolazine produced similar 
improvements in exercise parameters, nitroglycerin use, Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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and anginal frequency in diabetic (n = 189) and nondiabetic 
(n = 634) patients at 12 weeks. Post hoc analysis of the long-
term open-label extension period of the CARISA trial found 
that ranolazine 750 mg and 1000 mg compared with placebo 
reduced glycosylated hemoglobin (HbA1c) by 0.48 ± 0.18% 
(P = 0.008) and 0.70 ± 0.18% (P = 0.0002), respectively.37 
HbA1c was not a preplanned efficacy variable in the CARISA 
trial, and hypoglycemia therapy was not controlled, but the 
statistical significance of these findings support an effect of 
ranolazine.
Subsequently, a prospective evaluation of the effect of rano-
lazine on hyperglycemia was performed as part of the MERLIN 
trial. Ranolazine, compared with placebo,   significantly reduced 
HbA1c at four months (5.9% versus 6.2%; P , 0.001).60 In 
patients with diabetes treated with ranolazine, HbA1c declined 
from 7.5 to 6.9 (P , 0.001). Diabetic patients were more likely 
to achieve HbA1c , 7% at four months with ranolazine com-
pared with placebo (59% versus 49%; P , 0.001) and were 
less likely to have a .1% increase in HbA1c (14.2% versus 
20.6% at one year; P , 0.001).
The exact mechanism for the positive glycometabolic 
effect of ranolazine seen in these trials is unclear. Improved 
angina control and exercise tolerance with ranolazine can 
lead to improved cardiovascular health. The amount of 
exercise needed, however, to reduce the HbA1c to the extent 
seen in these trials is unlikely to be achieved in this elderly 
population with angina.37 It is also unlikely that ranola-
zine had any significant effect on erythrocyte lifespan or 
glucuronidation of hemoglobin that would ultimately affect 
HbA1c.59 Experimental models suggest that ranolazine may 
increase glucose-stimulated insulin secretion in pancreatic 
islet cells in response to glucose loading, but this finding has 
yet to be validated. Ultimately, further studies exploring the 
mechanism of ranolazine’s clinically significant reductions 
in HbA1c are needed.
Conclusions
Medical therapy for chronic stable angina underwent little 
advancement over the past quarter century until ranolazine’s 
approval in 2006. Ranolazine is a late INa inhibitor that prevents 
pathologic intracellular calcium accumulation in the setting 
of ischemia and/or heart failure. Multiple clinical trials have 
demonstrated the clinical utility of ranolazine in controlling 
angina symptoms and improving exercise tolerance in patients 
with coronary heart disease. Ranolazine is safe for use in 
patients with stable coronary heart disease and is without 
significant hemodynamic effects. Therefore, ranolazine is 
an ideal antianginal agent, where titration of traditional 
agents (beta-blockers, calcium channel blockers, or nitrates) 
is limited by bradycardia, hypotension, or reactive airway 
disease. Although revised labeling indicates that ranolazine 
is approved as the initial antianginal agent, the use of beta-
blockers should still be considered as first-line, due to their 
proven mortality reduction post-myocardial infarction.
The minimal QTc prolongation seen with ranolazine is 
without apparent clinical sequelae. In fact, investigational 
applications of ranolazine suggest an antiarrhythmic property. 
Ranolazine’s unique mechanism of action has led to other 
experiments suggesting that ranolazine may provide beneficial 
effects on heart failure and diabetes control. Although these 
latter indications have yet to be validated in large clinical trials, 
they are promising and warrant further investigation. Ulti-
mately, ranolazine is a safe and effective antianginal agent with 
a proven safety profile and a novel mechanism of action which 
may lead to further indications beyond angina control.
Disclosure
NKW has been a consultant to Gilead Sciences,   AstraZeneca, 
Abbott Women’s Advisory Board, Merck, Pfizer,   Boston 
  Scientific, Medtronic Women’s CV Health Advisory Panel, 
and Genzyme. She has also received research grants 
from Pfizer, Merck, NHLBI, Gilead Sciences, Abbott, 
  sanofi-aventis and Eli Lilly.
References
  1.  Brunton TL. On the use of nitrite of amyl in angina pectoris. Lancet. 
1867;90:97–98.
  2.  Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke sta-
tistics 2008 update: A report from the American Heart Association 
Statistics Committee and Stroke Statistics Committee. Circulation. 
2008;117:e25–e146.
  3.  Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy 
with or without PCI for stable coronary disease. N Engl J Med. 
2007;356:1503–1516.
  4.  Frye RL, August P, Brooks MM, et al; BARI 2D Study Group. 
A randomized trial of therapies for Type 2 diabetes and coronary artery 
disease. N Engl J Med. 2009;360:2503–2515.
  5.  Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after 
myocardial infraction: Systematic review and meta regression analysis. 
Br Med J. 1999;318:1730–1737.
  6.  Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy 
improve clinical outcomes of acute myocardial infarction after 
successful primary angioplasty? J Am Coll Cardiol. 2004;43: 
1773–1779.
  7.  Fraker TD, Fihn SD. 2007 chronic angina focused update of the ACC/
AHA 2002 guidelines for the management of patients with chronic 
stable angina. J Am Coll Cardiol. 2007;50:2264–2274.
  8.  Vadnais DS, Wenger NK. Management options in chronic stable angina 
pectoris: Focus on ranolazine. Clin Med Ther. 2009;1:871–877.
  9.  Bers DM, Barry WH, Despa S. Intracellular Na+ regulation in cardiac 
myocytes. Cardiovasc Res. 2003;57:897–912.
  10.  Murphy E, Cross H, Steenbergen C. Sodium regulation during isch-
emia versus reperfusion and its role in injury. Circ Res. 1999;84: 
1469–1470.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
529
Ranolazine in management of angina
  11.  Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/
persistent) sodium current: A potential drug target to reduce intracel-
lular sodium-dependent calcium overload and its detrimental effects on 
cardiomyocyte function. Eur Heart J. 2004;6 Suppl I:13–17.
  12.  Chaitman BR, Skettino SL, Parker JO, et al; MARISA Investigators. 
Anti-ischemic effects and long-term survival during ranolazine mono-
therapy in patients with chronic severe angina. J Am Coll Cardiol. 
2004;43:1375–1382.
  13.  MacInnes A, Fairman DA, Binding P, et al. The antianginal agent 
trimetazidine does not exert its functional benefit via inhibition of 
mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 
2003;93:e26–e32.
  14.  Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial 
fatty acid oxidation (pFOX) inhibitor, improves left ventricular 
function in dogs with chronic heart failure. J Card Fail. 2002;8: 
416–422.
  15.  McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine 
stimulates glucose oxidation in normoxic, ischemic, and reperfused 
ischemic rat hearts. Circulation. 1996;93:135–142.
  16.  Létienne R, Vié B, Puech A, Vieu S, Le Grand B, John GW. Evidence 
that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in 
the rat cardiovascular system. Naunyn Schmiedebergs Arch Pharmacol. 
2001;363:464–471.
  17.  Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. 
A comparison between ranolazine and CVT-4325, a novel inhibitor 
of fatty acid oxidation, on cardiac metabolism and left ventricular 
  function in rat isolated perfused heart during ischemia and reperfusion. 
J Pharmacol Exp Ther. 2007;321:213–220.
  18.  Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late 
sodium current inhibition as a new cardioprotective approach. J Mol 
Cell Cardiol. 2008;44:954–967.
  19.  Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium cur-
rent as a potential cardioprotective principle: Effects of the late sodium 
current inhibitor ranolazine. Heart. 2006;92 Suppl IV:6–14.
  20.  Chaitman BR. Ranolazine for the treatment of chronic angina 
and potential use in other cardiovascular conditions. Circulation. 
2006;113:2462–2472.
  21.  Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiologi-
cal effects of ranolazine, a novel antianginal agent with antiarrhythmic 
properties. Circulation. 2004;110:904–910.
  22.  Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic 
effects of ranolazine in canine pulmonary vein sleeve preparations. 
Heart Rhythm. 2008;5:1019–1026.
  23.  Song Y, Shryock JC, Belardinelli L. An increase of late sodium cur-
rent induces delayed afterdepolarizations and sustained triggered 
activity in atrial myocytes. Am J Physiol Heart Circ Physiol. 2008; 
294:H2031–H209.
  24.  Undrovinas A, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine 
improves abnormal repolarization and contraction in left ventricular 
myocytes of dogs with heart failure by inhibiting late sodium current. 
J Cardiovasc Electrophysiol. 2006;17 Suppl 1:S169–S177.
  25.  Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of 
the pro-arrhythmic effects of increasing late INa in guinea pig ventricular 
myocytes. J Cardiovasc Pharmacol. 2004;44:192–199.
  26.  Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of 
ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 
2005;95:311–336.
  27.  Chaitman BR, Pepine CJ, Parker J, et al. Effects of ranolazine with 
atenolol, amlodipine, or diltiazem on exercise tolerance and angina fre-
quency in patients with chronic severe angina: A randomized   controlled 
trial. JAMA. 2004;291:309–316.
  28.  Stone P, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal 
efficacy of ranolazine when added to treatment with amlodipine: The 
ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll 
Cardiol. 2006;48:566–575.
  29.  FDA.gov. Ranexa (Ranolazine); updated June 19, 2009. http://www.
fda.gov/. Accessed May 21, 2010.
  30.  Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE.   
A study of the effects of ranolazine using automated quantitative 
  analysis of serial myocardial perfusion images. JACC Cardiovasc 
Imaging. 2009;2:1301–1309.
  31.  Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects 
of ranolazine on recurrent cardiovascular events in patients with 
non-ST-elevation acute coronary syndromes. JAMA. 2007;297: 
1775–1783.
  32.  Scirica BM, Morrow DA, Budaj A, et al. Ischemia detected on continu-
ous electrocardiography after acute coronary syndrome: Observations 
from the MERLIN-TIMI 36 (metabolic efficiency with ranolazine 
for less ischemia in non-ST-elevation acute coronary syndrome – 
  thrombolysis in myocardial infarction 36) trial. J Am Coll Cardiol. 
2009;53:1411–1421.
  33.  Wenger NK, Chaitman B, Vetrovec GW. Gender comparison of efficacy 
and safety of ranolazine for chronic angina pectoris in four randomized 
clinical trials. Am J Cardiol. 2007;99:11–18.
  34.  Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine 
in patients with chronic angina: Observations from the randomized, 
  double-blind, placebo-controlled MERLIN-TIMI (metabolic efficiency 
with ranolazine for less ischemia in non-ST-segment elevation acute cor-
onary syndromes) 36 trial. J Am Coll Cardiol. 2009;53:1510–1516.
  35.  Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel 
antianginal agent in patients with severe chronic stable angina: The 
ranolazine open label experience (ROLE). J Am Coll Cardiol. 2007;49: 
1027–1034.
  36.  Rich MW, Crager M, McKay CR. Safety and efficacy of extended-
release ranolazine in patients aged 70 years or older with chronic stable 
angina pectoris. Am J Geriatr Cardiol. 2007;16:216–221.
  37.  Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exer-
cise tolerance and HbA1c in patients with chronic angina and diabetes. 
Eur Heart J. 2006;27:42–48.
  38.  Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacoki-
net. 2006;45:469–491.
  39.  Jerling M, Abdallah H. Effect of renal impairment on multiple-dose 
pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther. 
2005;78:288–297.
  40.  Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-
dose pharmacokinetics of ranolazine sustained-release tablets. J Clin 
Pharmacol. 2005;45:802–809.
  41.  Jerling M, Huan BL, Leung K, Chu N, Abdallah H, Hussein Z. Studies 
to investigate the pharmacokinetic interactions between ranolazine and 
ketoconazole, diltiazem or simvastatin during combined administration 
in healthy subjects. J Clin Pharmacol. 2005;45:422–433.
  42.  Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L,   Antzelevitch C. 
Atrial-selective sodium channel block as a strategy for suppression of 
atrial fibrillation. Ann N Y Acad Sci. 2008;1123:105–112.
  43.  Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect 
of ranolazine on maintaining sinus rhythm in patients with resistant 
atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8:175–181.
  44.  Murkock DK, Kersten M, Kaliebe J, Larrain G. The use of oral 
  ranolazine to convert new or paroxysmal atrial fibrillation: A review 
of experience with implications for possible “pill in the pocket” 
approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9: 
260–267.
  45.  Sossalla S, Kallmeyer B, Wagner S, et al. Altered Na+ currents in 
atrial fibrillation: Effects of ranolazine on arrhythmias and con-
tractility in human atrial myocardium. J Am Coll Cardiol. 2010;55: 
2330–2342.
  46.  Kumar K, Nearing BD, Bartoli CR, Kwaku KF, Belardinelli L, 
  Verrier RL. Effect of ranolazine on ventricular vulnerability and defibril-
lation threshold in the intact porcine heart. J Cardiovasc Electrophysiol. 
2008;19:1073–1079.
  47.  Dhalla AK, Wang WQ, Dow J, et al. Ranolazine, an antianginal 
agent, markedly reduces ventricular arrhythmias induced by isch-
emia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 
2009;297:H11923–H11929.Therapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
530
Vadnais and Wenger
  48.  Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic 
effects of (±)-N-(2,6-Dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxy-
phenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. 
J Pharmacol Exp Ther. 2008;325:875–881.
  49.  Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. 
Ranolazine shortens repolarization in patients with sustained inward 
sodium current due to type-3 long QT syndrome. J Cardiovasc 
  Electrophysiol. 2008;19:1289–1293.
  50.  Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antiangi-
nal agent with novel electrophysiological properties, on the incidence of 
arrhythmias in patients with non-ST-segment elevation acute coronary 
syndrome: Results from the metabolic efficiency with ranolazine for less 
ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in 
myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled 
trial. Circulation. 2007;116:1647–1652.
  51.  Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine 
on left ventricular regional diastolic function in patients with ischemic 
heart disease. Cardiovasc Drugs Ther. 1994;8:741–747.
  52.  Hwang H, Arcidi JM Jr, Hale SL, et al. Ranolazine as a cardioplegia 
additive improves recovery of diastolic function in isolated rate hearts. 
Circulation. 2009;120 Suppl 1:S16–S21.
  53.  Wu Y, Song Y, Belardinelli L, Shryock JC. The late Na+ current 
(INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine 
to increase late INa and cause ventricular diastolic dysfunction. 
J   Pharmacol Exp Ther. 2009;330:550–557.
  54.  Sossalla S, Wagner S, Rasenack ECL, et al. Ranolazine improves 
diastolic dysfunction in isolated myocardium from failing human 
hearts – role of late sodium current and intracellular ion accumulation. 
J Mol Cell Cardiol. 2008;45:32–43.
  55.  Hale SL, Leeka JL, Kloner RA. Improved left ventricular function and 
reduced necrosis after myocardial ischemia/reperfusion in rabbits treated 
with ranolazine, an inhibitor of the late sodium channel. J Pharmacol 
Exp Ther. 2006;318:418–423.
  56.  Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enal-
april or metoprolol prevents progressive LV dysfunction and remodeling 
in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. 
2008;295:H2149–H2155.
  57.  Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with 
ranolazine improves mechanical efficiency in dogs with chronic heart 
failure. Circ Res. 2002;91:278–280.
  58.  Stone P. Ranolazine: New paradigm for management of myocardial 
ischemia, myocardial dysfunction, and arrhythmias. Cardiol Clin. 
2008;26:603–614.
  59.  Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular 
disease: A statement for healthcare professionals from the American 
Heart Association. Circulation. 1999;100:1134–1146.
  60.  Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the 
  glycometabolic effects of ranolazine in patients with and without dia-
betes mellitus in the MERLIN-TIMI 36 randomized controlled trial. 
Circulation. 2009;119:2032–2039.